Clinical Trial · NCT06916637

Clinical Study on the Application of 18F-HER2 Affibody PET Imaging in HER2-Expressing Breast Cancer

Overview

This study aims to evaluate the clinical utility of 18F-labeled HER2 Affibody PET for diagnosing and monitoring HER2-expressing breast cancer. HER2, a protein overexpressed in certain malignancies including breast cancer, serves as a critical biomarker for targeted therapies.The HER2 Affibody-an engineered 7 kDa protein with nanomolar affinity for HER2-leverages its rapid tumor penetration and clearance kinetics to achieve high-contrast PET imaging. This study aims to evaluate the diagnostic efficacy of 18F-HER2 Affibody PET in early detection, clinical staging, and treatment response monitoring, thereby providing novel imaging evidence to guide personalized therapeutic strategies for patients with HER2-expressing breast cancer.

Sponsor

The Affiliated Hospital of Qingdao University

Phase

N/A

Contacts

Zhenguang Wang

wangzhenguang@qdu.edu.cn

+86-0532-82913318

ClinicalTrials.gov

NCT06916637

Drug / Compound

18F-labeled HER2 Affibody

Isotope(s):

Target(s):

HER2